Seres Therapeutics Inc (MCRB) — Cash Flow-to-Debt Ratio
Seres Therapeutics Inc (MCRB) has a Cash Flow-to-Debt Ratio of -0.33x as of June 2026, meaning its operating cash flow of $-22.39 Million could theoretically repay 0% of its total liabilities ($67.05 Million) in one year. See MCRB FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Seres Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Seres Therapeutics Inc across 14 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Seres Therapeutics Inc.
Annual Cash Flow-to-Debt Ratio for Seres Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Seres Therapeutics Inc. Check MCRB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | $1.12 Million | $93.97 Million | ▲ +101.0% |
| 2024 | -1.18x | $-148.61 Million | $126.03 Million | ▼ -305.4% |
| 2023 | -0.29x | $-117.35 Million | $403.46 Million | ▲ +57.0% |
| 2022 | -0.68x | $-228.82 Million | $338.00 Million | ▼ -2360.8% |
| 2021 | 0.03x | $6.69 Million | $223.35 Million | ▲ +105.4% |
| 2020 | -0.56x | $-93.61 Million | $168.19 Million | ▼ -31.5% |
| 2019 | -0.42x | $-76.52 Million | $180.76 Million | ▼ -13.5% |
| 2018 | -0.37x | $-62.85 Million | $168.52 Million | ▲ +36.4% |
| 2017 | -0.59x | $-75.52 Million | $128.82 Million | ▼ -286.9% |
| 2016 | 0.31x | $43.92 Million | $140.01 Million | ▲ +108.8% |
| 2015 | -3.55x | $-40.84 Million | $11.51 Million | ▼ -4837.3% |
| 2014 | -0.07x | $-10.36 Million | $144.07 Million | ▲ +98.0% |
| 2013 | -3.56x | $-5.32 Million | $1.49 Million | ▲ +78.3% |
| 2012 | -16.43x | $-2.92 Million | $178.00K | — |